Welcome to our dedicated page for ORGANON & CO news (Ticker: OGN), a resource for investors and traders seeking the latest updates and insights on ORGANON & CO stock.
Organon & Co (OGN) delivers science-driven healthcare solutions through its focus on women’s health, biosimilars, and established medicines. This page provides investors and industry professionals with a centralized hub for tracking the company’s latest developments and strategic initiatives.
Access real-time updates including earnings reports, regulatory milestones, product launches, and partnership announcements. Our curated collection ensures you stay informed about OGN’s progress in addressing global healthcare needs while maintaining compliance with evolving industry standards.
Key updates cover clinical trial results, market expansion efforts, and leadership changes impacting OGN’s operations across Europe, North America, and Asia-Pacific regions. All content is verified for accuracy to support informed analysis of the company’s pharmaceutical innovations and business strategy.
Bookmark this page for streamlined access to Organon &’s official communications and third-party analyses. Regularly updated content helps stakeholders monitor the company’s position in competitive therapeutic markets and evolving healthcare landscapes.
Shanghai Henlius Biotech and Organon announced that the European Medicines Agency (EMA) has validated the marketing authorization applications for HLX14. HLX14 is a biosimilar candidate for Prolia® and Xgeva® (denosumab), used primarily to treat osteoporosis in postmenopausal women at high risk for fractures. The applications are based on a comprehensive phase 3 clinical study comparing HLX14 with EU-sourced reference denosumab. In 2022, Henlius granted Organon exclusive commercialization rights for HLX14 in the EU, US, and Canada, excluding China. Notably, 32 million Europeans aged 50 or above suffer from osteoporosis, highlighting the market potential for HLX14.
Organon, a global healthcare company focusing on women's health, announced the pricing of $1.0 billion Senior Notes Offering, consisting of $500 million of 6.750% senior secured notes and $500 million of 7.875% senior unsecured notes. The proceeds will be used to repay borrowings and cover related expenses. The offering is expected to close on May 17, 2024.
Organon, a global healthcare company focusing on women's health, plans to offer $1.0 billion in senior notes, consisting of $500 million in secured notes and $500 million in unsecured notes. The proceeds will be used to repay borrowings and cover related expenses. The offering is not registered under the U.S. Securities Act and is targeted at qualified institutional buyers and non-U.S. persons.
Organon (NYSE: OGN) reported impressive first-quarter 2024 results, with revenue reaching $1,622 million, up 5% on an as-reported basis and 7% at constant currency. Diluted earnings per share were $0.78, with non-GAAP adjusted earnings per share at $1.22. The company reaffirmed its full-year 2024 financial guidance. Women's Health revenue grew by 11%, Biosimilars revenue by 46%, and Established Brands revenue remained flat. Overall, Organon had a solid start to the year, focusing on growth while maintaining its commitment to improving women's health.
